InterMune (NASDAQ:ITMN) was the big winner in biotech today, up around 10% on rumors of a buyout. However, in this video from Friday's Market Checkup, Motley Fool health-care analyst David Williamson says that these rumors are as of yet completely unsubstantiated, and should not constitute an investing thesis.

He does discuss, however, why the company would make an attractive acquisition. Its first-in-class idiopathic pulmonary fibrosis drug Esbriet recently passed a new phase 3 trial, and is up again for FDA approval; the drug was approved in Europe in 2011. Esbriet makes up the entirety of InterMune's value, which makes it a very pure play, and a nice addition to just about any company's portfolio. David makes a prediction for who may buy the company down the road, discusses how big the upside could be for the drug, and cautions investors regarding how the downside could look, as well.

David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.